Cefaclor treatment of upper and lower respiratory tract infections caused by Moraxella catarrhalis.
A retrospective analysis of data from 18 clinical studies was performed to examine the effectiveness and safety of cefaclor in the treatment of upper and lower respiratory tract infections caused by Moraxella catarrhalis (previously called Branhamella catarrhalis). Eighty-six percent of 56 evaluable patients had improvement in their symptoms of infections following therapy with cefaclor. There were no serious or life-threatening adverse drug experiences reported by any patient. Cefaclor appears to be an appropriate antibiotic for the safe and effective treatment of respiratory tract infections caused by M. catarrhalis.
Oberlin
J A
JA
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN.
Hyslop
D L
DL
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002433:Cefaclor / Q000009:adverse effects / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D001936:Moraxella catarrhalis; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012189:Retrospective Studies
D002433:Cefaclor; D002506:Cephalexin